Skip to main content

Table 2  Baseline characteristics of gastric cancer patients per diabetes mellitus and medications

From: Prognostic value of long-term antidiabetic and antihypertensive therapy in postoperative gastric cancer patients: the FIESTA study

Characteristics

no DM

Treated DM (

Untreated DM

P

Number

2036

243

733

 

Age (year)

57.95 (11.26)

61.43 (10)

59.19 (11.54)

< 0.001

Male (N%)

1551 (76.18%)

179 (73.66%)

509 (69.44%)

0.002

Smoking (N %)

381 (21.12%)

44 (18.11%)

131 (17.90%)

0.137

Alcohol (N %)

120 (6.66%)

19 (7.82%)

29 (3.96%)

0.017

Family history (N %)

178 (9.87%)

26 (10.70%)

54 (7.39%)

0.109

BMI (kg/m2)

22.43 (2.86)

24.02 (3.4)

23.35 (3.28)

< 0.001

Metformin (N %)

NA

170 (69.96%)

NA

 

Sulfonylurea (N %)

NA

54 (22.22%)

NA

 

Glucosidase inhibitor (N %)

NA

4 (1.65%)

NA

 

Insulin (N %)

NA

5 (2.06%)

NA

 

Unclear (N %)

NA

22 (9.05%)

NA

 

SBP (mmHg)

122.46 (18.65)

126.49 (19.61)

133.65 (21.77)

< 0.001

DBP (mmHg)

76.51 (11.16)

77.92 (11.47)

78.42 (12.94)

0.001

FPG (mmol/L)

4.87 (0.74)

8.49 (2.61)

9.15 (2.67)

< 0.001

TG (mmol/L)

1.09 (0.71)

1.55 (1.27)

1.37 (1.05)

< 0.001

TC (mmol/L)

4.49 (1)

4.59 (1.03)

4.57 (1.24)

< 0.001

HDL (mmol/L)

1.1 (0.35)

0.92 (0.34)

0.93 (0.47)

0.011

LDL (mmol/L)

2.95 (0.88)

2.99 (0.92)

3.04 (1.02)

0.293

TNM stage (N%)

   

< 0.001

 I

280 (14.97%)

30 (12.35%)

34 (4.66%)

 

 II

314 (16.78%)

38 (15.64%)

72 (9.88%)

 

 III

1048 (56.01%)

146 (60.08%)

422 (57.89%)

 

 IV

229 (12.24%)

29 (11.93%)

201 (27.57%)

 

Pathological type (N%)

   

0.252

 Adenocarcinoma

1426 (78.74%)

181 (74.79%)

540 (74.59%)

 

 Signet-ring cell

357 (19.71%)

54 (22.31%)

171 (23.62%)

 

 Neuroendocrine

14 (0.77%)

4 (1.65%)

7 (0.97%)

 

 Other

14 (0.77%)

3 (1.24%)

6 (0.83%)

 

Differentiated

   

< 0.001

 High

25 (1.38%)

3 (1.24%)

6 (0.83%)

 

 Middle

734 (40.55%)

90 (37.19%)

222 (30.66%)

 

 Low

1051 (58.07%)

149 (61.57%)

496 (68.51%)

 

Chemotherapy (N %)

608 (29.8%)

101 (32.4%)

151 (30.4%)

0.010

Chemotherapy courses (N)

3.51 (2.4)

4.09 (2.4)

3.61 (2.3)

0.078

  1. Data are represented as mean (standard deviation) or count (percentage%)
  2. Chi-square test for Categorical variables and ANOVA or Kruskal–Wallis test when nonparametric for continuous variables were used. HT, hypertension; DM, diabetes mellitus; Alcohol: alcohol use history; Smoking: tobacco use history; Family history, Family history of cancer; BMI, Body mass index; CCB: calcium channel blockers, ACEI: angiotensin-converting enzyme inhibitors, ARB: angiotensin receptor blocker, β-blocker: beta-receptor antagonists; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TG, Triglyceride; TC, Total Cholesterol; LDL, Low-density Lipoprotein; HDL, High-density Lipoprotein